Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12458172 | 0.91 | ALDH1A1 (0.34) | POLBALDH1A1PKMHDAC3HDAC4 | |
| SCHEMBL15197949 | 0.90 | ALDH1A1 (0.34) | POLBALDH1A1PKMGAAHDAC3 | |
| SCHEMBL23714916 | 0.88 | ALDH1A1 (0.36) | POLBALDH1A1GAAHDAC3HDAC4 | |
| SCHEMBL278650 | 0.88 | ALDH1A1 (0.36) | POLBALDH1A1GAAHDAC3HDAC4 | |
| SCHEMBL24979407 | 0.87 | HDAC3 (0.38) | POLBALDH1A1GAAHDAC3HDAC4 | |
| SCHEMBL3018592 | 0.86 | POLB (0.34) | POLBALDH1A1PKMGAAHDAC3 | |
| SCHEMBL23651513 | 0.85 | POLB (0.32) | POLBALDH1A1PKM | |
| SCHEMBL4741523 | 0.85 | POLB (0.32) | POLBGAA | |
| SCHEMBL18326853 | 0.85 | ALDH1A1 (0.34) | POLBALDH1A1PKMGAAHDAC3 | |
| SCHEMBL836363 | 0.84 | ALDH1A1 (0.37) | POLBALDH1A1PKMHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SEAGEN INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SEAGEN INC. | 2024-07-11 | — | — | US | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | GENENTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024052333-A1 | MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2024-03-14 | — | — | WO | disclosed |
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | GENENTECH, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240018141-A1 | IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2024-01-18 | — | — | US | disclosed |
| US-20240018141-A1 | IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2024-01-18 | — | — | US | disclosed |
| US-20080254024-A1 | ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME | GENENTECH, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080247951-A1 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-7375078-B2 | Heterocyclic self-immolative linkers and conjugates | GENENTECH, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375078-B2 | Heterocyclic self-immolative linkers and conjugates | GENENTECH, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080057066-A1 | METHODS AND COMPOSITIONS FOR TARGETING RELT | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070218069-A1 | antibodies that specifically binds ubiquitin comprising a lysine linkage between a lysine residue of one ubiquitin molecule and the C-terminal glycine residue of another ubiquitin molecule | GENENTECH, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070081995-A1 | Methods and compositions for targeting IFNAR2 | GENENTECH, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | CD79B, CD99, BCL6 | POLB 1339/4885ALDH1A1 2981/4885PKM 4789/4885 |
| US-20070081995-A1 | Methods and compositions for targeting IFNAR2 | IFNAR1, IFNG, EIF2AK2 | POLB 65/4885ALDH1A1 4868/4885PKM 4572/4885 |
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPCAM, TOP2A, SPAG5 | POLB 2525/4885ALDH1A1 388/4885PKM 3976/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | POLB 3279/4885ALDH1A1 3778/4885PKM 4238/4885 |
| US-20070218069-A1 | antibodies that specifically binds ubiquitin comprising a lysine linkage between a lysine residue of one ubiquitin molecule and the C-terminal glycine residue of another ubiquitin molecule | STUB1, UBQLN1, UBAP2 | POLB 2165/4885ALDH1A1 3778/4885PKM 4366/4885 |
| US-20240018141-A1 | IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES | CD74, TLR9, TLR1 | POLB 3846/4885ALDH1A1 517/4885PKM 3376/4885 |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | TOP2A, TOP1, XPA | POLB 2068/4885ALDH1A1 1163/4885PKM 3964/4885 |
| US-20080057066-A1 | METHODS AND COMPOSITIONS FOR TARGETING RELT | REL, FCGRT, IL6ST | POLB 1085/4885ALDH1A1 4724/4885PKM 4415/4885 |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | CD22, CD2BP2, CD2 | POLB 4774/4885ALDH1A1 404/4885PKM 4840/4885 |
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | PSMG3, STUB1, USP47 | POLB 1001/4885ALDH1A1 4718/4885PKM 4057/4885 |
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | POLB 451/4885ALDH1A1 115/4885PKM 2303/4885 |
| US-20080247951-A1 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR | IGSF11, MRPS18A, ANXA4 | POLB 3002/4885ALDH1A1 2472/4885PKM 4883/4885 |
| US-20080254024-A1 | ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME | EPHB2, EPHB3, EPHB1 | POLB 1758/4885ALDH1A1 2530/4885PKM 4785/4885 |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | LNPEP, CSTB, ALB | POLB 1279/4885ALDH1A1 771/4885PKM 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.